Lung cancer in patients under the age of 40 years

Kozielski, Jerzy; Kaczmarczyk, Grzegorz; Porębska, Irena; Szmygin-Milanowska, Katarzyna; Gołecki, Marcin

doi:10.5114/wo.2012.31770

Cited by 26 publications

(28 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…FLC patients tended to have more AD histology, other cancer history, distant organ metastasis and stage IV cases, the latter two are indicator of increased cancer aggressiveness. Studies on young lung cancer patients also supported high AD ratio, prevalence of female and diagnosed in advanced stages (25, 26, 28, 29). Other interesting results included: the age curve of our FLC and sporadic males separated clearly, while age curve of our FLC and sporadic females almost overlapped with each other (Figures 4F,H).…”

Section: Discussionmentioning

confidence: 74%

Characteristics of Familial Lung Cancer in Yunnan-Guizhou Plateau of China

et al. 2018

View full text Add to dashboard Cite

Background: Lung cancer has inherited susceptibility and show familial aggregation, the characteristics of familial lung cancer exhibit population heterogeneity. Despite previous studies, familial lung cancer in China's Yunnan-Guizhou plateau remains understudied.Methods: Between 2015 and 2017, 1,023 lung cancer patients (residents of Yunnan-Guizhou plateau) were enrolled with no limitation on other parameters, 152 subjects had familial lung cancer. Clinicopathologic parameters were analyzed and compared, 4,754 lung cancer patients from NCI-GDC were used to represent a general population.Results: Familial lung cancer (FLC) subjects showed unique characters: early-onset; increased rate of female, adenocarcinoma, stage IV and other cancer history; unbalance in anatomic sites; all ruling out significant difference in smoking status. Unbalanced distribution of co-existing diseases or symptoms was also discovered. FLC patients were more likely to develop benign lesions (polyps, nodules, cysts) early in life, especially early-growth of multiple pulmonary nodules at higher frequency. Typical diseases with family history like diabetes and hypertension were also increased in FLC population. Compared to GDC data, our subject population was younger: the age peak of our FLC group was in 50–59; our sporadic group had an age peak around 60; while GDC patients' age peak was in 60–69. Importantly, the biggest difference happened in age 40–49: our FLC group and sporadic group had 3 times and 2 times higher ratio than GDC population, respectively. Moreover, the age peaks of our FLC males and FLC females were both in 50–59; while our sporadic females had the age peak in 50–59, much earlier than sporadic males (around 60–69); reflecting gender-specific or age-specific characters in our subject population.Conclusions: Familial lung cancer in China's Yunnan-Guizhou plateau showed unique clinicopathologic characters, differences were found in gender, age, histologic type, TNM stage and co-existing diseases or symptoms. Identification of hereditary factors which lead to increased lung cancer risk will be a challenge of both scientific and clinical significance.

show abstract

Section: Discussionmentioning

confidence: 74%

Characteristics of Familial Lung Cancer in Yunnan-Guizhou Plateau of China

et al. 2018

View full text Add to dashboard Cite

show abstract

“…Lung cancer, in both sexes combined, was the most commonly diagnosed cancer (2.1 million new cases, 11.6% of the total cancer cases) and the leading cause of cancer death (1.8 million deaths, 18.4% of the total cancer deaths) in 2018 [1]. Although lung cancer occurs in adult patients of all ages, it predominates among people over 50 years old, most often at the age of 60-75 years [2]. Unsurprisingly, comorbidities are common in patients with lung cancer, including diabetes.…”

Section: Introductionmentioning

confidence: 99%

A Cohort Study of Exposure to Antihyperglycemic Therapy and Survival in Patients with Lung Cancer

Danila

Linkeviciute-Ulinskiene

Zablockis

et al. 2020

IJERPH

View full text Add to dashboard Cite

We evaluated the effect of antihyperglycemic therapy on the survival of patients with lung cancer (LC). The analysis included patients with LC and concomitant type 2 diabetes. 15,929 patients were classified into five groups: metformin users, insulin users, metformin and insulin users, sulphonylurea users and non-diabetic group. A multivariate analysis showed that exposure to either metformin or to insulin was associated with a lower risk of LC-specific mortality, and this approached statistical significance (HR 0.82, 95% CI 0.72-92 for metformin and HR 0.65, 95% CI 0.44-95 for insulin). When deaths from all causes were considered, only metformin exposure was associated with a significantly lower risk of death (HR 0.82, 95% CI 0.73-0.92). Users of sulphonylurea were at a higher risk of LC-specific and overall mortality (HRs 1.19, 95% CI 0.99-1.43 and 1.22, 95% CI 1.03-1.45). Our study shows a positive effect of metformin on the survival of patients with LC. Moreover, our results show that exposure to insulin was associated with a lower risk of LC-specific mortality, but not with deaths from all causes. The study results suggested that users of sulphonylurea may be at a higher risk of LC-specific and overall mortality.

show abstract

“…When a young male patient, in the third decade of life, presents with a lung mass and large pleural and pericardial effusion, amongst the most common pathologies initially considered are lymphoma, sarcoma, testicular carcinoma, and primary lung carcinoma. A review of the literature revealed about 2-5% of all lung cancer cases involve patients with an average age of 34 years, equal rates in men and women, and adenocarcinoma is the most common type of lung cancer [1,2]. A careful review of the past medical history, initial presentation, and physical exam findings are important to determine the initial workup and treatment.…”

Section: Introductionmentioning

confidence: 99%